Resoundant
Resoundant commercializes Magnetic Resonance Elastography (MRE), an FDA-cleared non-invasive MRI-based liver fibrosis assessment technology invented at Mayo Clinic, serving radiology providers, hepatology practices, pharmaceutical trial sponsors, and liver disease patients.
- Company typePrivate
- Founded2006
- HeadquartersRochester, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Resoundant does
Resoundant, Inc. is a privately held medical technology company headquartered in Rochester, Minnesota that commercializes Magnetic Resonance Elastography (MRE), a non-invasive imaging technology invented at Mayo Clinic by CEO Richard Ehman and colleagues in the 1990s. MRE is an FDA-cleared software and hardware upgrade deployed on existing MRI systems; it converts MR phase data into quantitative, reproducible measurements of tissue stiffness (in kilopascals) using standardized computational algorithms that produce biomarkers of liver fibrosis consistent across operators, scanners, and field strengths. The product portfolio includes the core 2D MRE technology, the advanced 3D MRE and Hepatogram+ multiparametric package for clinical trials, the Flex Driver hardware system that generates shear waves, the MRI-PDFF companion technology for hepatic steatosis quantification, and the MRE:connect patient-facing directory of imaging centers.
The company operates a hybrid business model. It licenses its MRE technology to the three global MRI manufacturers (GE Healthcare, Siemens Healthineers, Philips Healthcare), who embed it as FDA-cleared functionality on their scanners; it manufactures and sells Flex Driver hardware; it operates MRE:connect, a consumer-facing directory of 1,300+ US imaging centers offering MRE; and it provides core lab, central image read, and regulatory support services to pharmaceutical and biotech sponsors running NAFLD, NASH, and MASH clinical trials. Resoundant serves four primary customer segments: hospital radiology departments and imaging centers, hepatology and gastroenterology practices, pharmaceutical and biotech companies conducting liver disease trials, and patients with chronic liver disease. The technology is FDA-cleared, reimbursed under CMS Category I CPT code 76391 at approximately $240 per exam, and recognized by the American College of Radiology as the most accurate non-invasive liver fibrosis exam. As of 2024, MRE is available at more than 2,500 imaging centers globally.
Resoundant firmographics
Firmographics- Name
- Resoundant
- Legal name
- Resoundant, Inc.
- Website
- https://resoundant.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Resoundant commercializes Magnetic Resonance Elastography (MRE), an FDA-cleared non-invasive MRI-based liver fibrosis assessment technology invented at Mayo Clinic, serving radiology providers, hepatology practices, pharmaceutical trial sponsors, and liver disease patients.
- Ownership category
- akta.pro rank
Where Resoundant is headquartered
LocationHeadquarters
- HQ city
- Rochester
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Resoundant business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- MRE Driver Hardware Systems: Resoundant designs and manufactures MRE driver systems (Flex Driver and active drivers) that generate low frequency mechanical waves transmitted to passive drivers placed on patients. These hardware systems are sold to MRI manufacturers and directly to imaging centers.
- Technology Licensing to MRI Manufacturers: Resoundant assists MRI manufacturers (GE, Siemens, Philips) in implementing MRE as FDA-cleared products. The company receives licensing royalties and ongoing revenue from these OEM partnerships.
- Clinical Trial Services: Resoundant provides central image reads, secure data management, quantitative reporting, site training and identification, regulatory support, study start-up/close-out support, quality control, and proprietary in-house analytics for pharmaceutical clinical trials. Revenue generated from consulting and core lab services for NAFLD/NASH trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standalone MRE Exam - Medicare Reimbursement |
| Unit Pricing | Pay-as-you-go | Combined MRE + PDFF Exam |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Resoundant product offering
Product offeringCore offering
Resoundant develops, manufactures, and licenses Magnetic Resonance Elastography (MRE) technology for non-invasive liver fibrosis assessment. The company provides MRE driver hardware systems and processing software to MRI manufacturers (GE Healthcare, Siemens, Philips) as FDA-cleared upgrades, and offers core lab clinical trial services directly to pharmaceutical companies for NAFLD/NASH drug development. Its proprietary technology converts MRI data into quantitative, reproducible biomarkers of liver stiffness.
Product overview
Resoundant offers a unified portfolio centered on Magnetic Resonance Elastography (MRE) technology for non-invasive liver disease diagnosis. The core product is FDA-cleared MRE, implemented as an upgrade across GE, Siemens, and Philips MRI systems. Key offerings include: MRE (core technology for liver stiffness measurement), Hepatogram+ (advanced multiparametric 3D MRE for clinical trials), Flex Driver (hardware component), PDFF imaging (companion fat quantification technology), MRE:connect (patient location service), and Clinical Trial Services (core lab and research support). The technology was invented at Mayo Clinic and enables quantitative, reproducible liver fibrosis assessment as an alternative to invasive biopsy.
Differentiator
Problem solved
Functional benefit
Brands
- MRE:connect: Online directory of leading radiology and imaging centers offering MR Elastography for liver fibrosis staging.
- Hepatogram+
Products and services
- Magnetic Resonance Elastography (MRE) FDA-cleared quantitative imaging technology that converts MRI data into precise, reproducible measurements of tissue stiffness for liver fibrosis assessment. Deployed as an upgrade to existing MRI systems at thousands of sites worldwide for non-invasive liver disease diagnosis.
- Hepatogram+
- Flex Driver
- MRE:connect Online directory of leading radiology and imaging centers offering MR Elastography for liver fibrosis staging, enabling patients to find and contact MRE-capable locations near them.
- Clinical Trial Services Core lab services for clinical trials including central image reads, secure data management, quantitative reporting, site training and identification, regulatory support, study start-up/close-out support, quality control, and proprietary in-house analytics for MRE and PDFF biomarkers.
Quantifiable outcome
- MRE diagnostic performance above 0.90 AUC for classifying all stages of liver fibrosis
- +5 more outcomes
Companies that use Resoundant
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Resoundant technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature8 records
Resoundant partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- Contract Research Organizations (CROs)coreResoundant leverages connections with talented contract research organizations across the globe for clinical trial services, providing core lab and central image read services for NAFLD/NASH trials.
- LITMUS Consortium (Pfizer, AstraZeneca, Bristol-Myers Squibb, Allergan, Echosens, HistoIndex)flagshipResoundant joined the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) project - a €46.5m European research initiative funded by the European Innovative Medicines Initiative. The consortium includes 53+ academic centers and pharmaceutical companies working to develop non-invasive diagnostic tests for NAFLD. Resoundant provides advanced 3D MRE software and technological expertise. Budget supported by EU and contributing industry partners including Pfizer (lead EFPIA partner), AstraZeneca, Bristol-Myers Squibb, Allergan, Echosens, and HistoIndex.
- Siemens HealthineerscoreResoundant partnered with Siemens to introduce MRE for their MRI systems, expanding global availability of the technology alongside GE and Philips implementations.
- Philips HealthcarecoreResoundant partnered with Philips Healthcare to implement MRE for their MRI systems. Philips has collaborated with Resoundant on MRE research, including work with Dr. Daniel Podberesky on pediatric MRE applications.
- GE HealthcarecoreGE Healthcare was the first MRI manufacturer to implement MRE as an FDA-cleared technology in 2009, making MRE available worldwide. Resoundant worked with GE to commercialize the technology as MR-Touch. GE continues as a key OEM partner implementing standardized MRE across their MRI systems.
- Mayo CliniccoreResoundant is a Mayo Clinic company founded by Mayo Foundation for Medical Education & Research, Mayo Clinic physicians and researchers. MRE was invented at Mayo Clinic and first implemented as a standard diagnostic test there in 2007. Mayo Clinic continues as key research and clinical development partner. Dr. Richard Ehman serves as both Mayo Clinic radiologist and Resoundant CEO.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
Resoundant competitors and assessment
Company assessmentOthers
- Hologic: Hologic is a women's-health and diagnostic imaging company with adjacent capability in clinical diagnostics and quantitative imaging biomarkers relevant to liver disease trial services.
- Canon Medical Systems: Canon Medical Systems is a major MRI manufacturer that competes in the scanner market where Resoundant's OEM partners compete, and could potentially license or develop elastography as an alternative to MRE.
- Median Technologies: Median Technologies provides imaging biomarkers and AI-based image analysis for oncology and liver clinical trials, offering central read and quantitative imaging services that overlap with Resoundant's clinical trial services franchise.
Broad incumbents
- Siemens Healthineers: Siemens Healthineers is an OEM licensee of MRE and a broad incumbent in MRI, with overlapping capability to develop proprietary elastography or substitute imaging modalities in the liver diagnostic space.
- GE Healthcare: GE Healthcare is both Resoundant's first OEM partner (MRE commercialized 2009) and a broader incumbent in MRI and diagnostic imaging that could develop or substitute competing elastography technologies.
- Philips Healthcare: Philips Healthcare licenses MRE and is a broad incumbent in MRI and diagnostic imaging with the resources to develop or substitute liver elastography capabilities across its installed base.
Direct peers
- HistoIndex: HistoIndex is a LITMUS consortium partner offering stain-free digital pathology for NASH/NAFLD assessment; it competes with MRE as an alternative non-invasive or minimally invasive biomarker approach in pharma trials and clinical research.
- Perspectum Diagnostics: Perspectum offers LiverMultiScan, an MRI-based multiparametric liver assessment that competes head-to-head with MRE for non-invasive liver fibrosis and steatosis quantification in clinical and trial settings.
- Echosens: Echosens manufactures FibroScan, the dominant ultrasound-based transient elastography device for liver fibrosis assessment, directly competing with MRE for first- and second-line liver fibrosis staging across hepatology practices.
Emerging players
- OWL (One Way Liver): OWL develops blood-based lipidomics biomarkers for NAFLD/NASH diagnosis and is part of the LITMUS consortium; it represents an emerging non-imaging alternative to MRE for fibrosis and steatosis assessment.
Market position
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Resoundant social profiles
Digital presenceResoundant compliance and trust
Trust signalCompliance1 record
Resoundant financial estimates
Financial estimateRevenue estimate
Valuation estimate
Resoundant leadership team
Management profileNumber of profiles
Profiles4 records
Resoundant funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Resoundant M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Resoundant
What does Resoundant do?
Resoundant develops, manufactures, and licenses Magnetic Resonance Elastography (MRE) technology for non-invasive liver fibrosis assessment. The company provides MRE driver hardware systems and processing software to MRI manufacturers (GE Healthcare, Siemens, Philips) as FDA-cleared upgrades, and offers core lab clinical trial services directly to pharmaceutical companies for NAFLD/NASH drug development. Its proprietary technology converts MRI data into quantitative, reproducible biomarkers of liver stiffness.
Is Resoundant a public or private company?
Resoundant is a private company. It is classified as corporate owned and is currently operating.
When was Resoundant founded?
Resoundant was founded in 2006. It employs 11 to 50 people.
Where is Resoundant based?
Resoundant is headquartered in Rochester, United States, in the North America region.
How does Resoundant make money?
Three revenue lines are on record. MRE Driver Hardware Systems are the primary driver. The others are technology Licensing to MRI Manufacturers and clinical Trial Services.
Who are Resoundant's main competitors?
Others on record are Hologic, Canon Medical Systems and Median Technologies. Broad incumbents are Siemens Healthineers, GE Healthcare and Philips Healthcare. Direct peers are HistoIndex, Perspectum Diagnostics and Echosens. OWL (One Way Liver) is listed as an emerging player.
Does Resoundant have an API?
No public API is recorded for Resoundant.